Characterization of the aryl hydrocarbon receptor as a potential candidate to improve cancer T cell therapies.
Saved in:
| Title: | Characterization of the aryl hydrocarbon receptor as a potential candidate to improve cancer T cell therapies. |
|---|---|
| Authors: | De Castro V; Université Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, 25000, Besançon, France., Abdellaoui O; Université Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, 25000, Besançon, France., Dehecq B; Université Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, 25000, Besançon, France., Ndao B; Université Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, 25000, Besançon, France., Mercier-Letondal P; Université Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, 25000, Besançon, France., Dauvé A; MGX-Montpellier GenomiX, Université de Montpellier, CNRS, INSERM, Montpellier, France., Garnache-Ottou F; Université Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, 25000, Besançon, France.; Service d'hématologie et d'immunologie cellulaire, Centre Hospitalier Universitaire de Besançon, Besançon, France., Adotévi O; Université Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, 25000, Besançon, France.; Service d'oncologie médicale, Centre Hospitalier Universitaire de Besançon, Besançon, France., Loyon R; Université Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, 25000, Besançon, France., Godet Y; Université Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, 25000, Besançon, France. yann.godet@univ-fcomte.fr. |
| Source: | Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2025 May 13; Vol. 74 (7), pp. 200. Date of Electronic Publication: 2025 May 13. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
